Craine, N, et al.
Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology and Infection
2009; 137: 1255–1265.
Miller, CL, et al.
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology
2002; 36: 737–742.
Health Protection Agency.
Shooting up: infections among people who inject drugs in the United Kingdom 2011
. London: Health Protection Agency Centre for Infections, 2012.
Public Health England Centre for Infections.
Hepatitis C in the UK
. London: Public Health England, 2013.
Van Den Berg, C, et al.
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction
2007; 102: 1454–1462.
Smyth, BP, et al.
Retrospective cohort study examining incidence of HIV and hepatitis C infection among injecting drug users in Dublin. Journal of Epidemiology and Community Health
2003; 57: 310–311.
Aarons, E, et al.
Failure to diagnose recent hepatitis C virus infections in London injecting drug users. Journal of Medical Virology
2004; 73: 548–553.
Balogun, MA, et al.
Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics. Epidemiology and Infection
2009; 137: 980–987.
Judd, A, et al.
Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. British Medical Journal
2005; 330: 24–25.
Turner, KM, et al.
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction
2011; 106: 1978–1988.
Brant, LJ, et al.
Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and high-risk English populations. Journal of Viral Hepatatis
2008; 15: 871–877.
Abou-Saleh, M, et al.
The effectiveness of behavioural interventions in the primary prevention of hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned. Harm Reduction Journal
2008; 5: 25.
Roy, KM, et al.
A method to detect the incidence of hepatitis C infection among injecting drug users in Glasgow 1993–98. Journal of Infection
2001; 43: 200–205.
Chawla, A, et al.
Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. Journal of Clinical Microbiology
2007; 45: 415–420.
Gaudy-Graffin, C, et al.
Use of an anti-hepatitis C virus (HCV) IgG avidity assay to identify recent HCV infection. Journal of Clinical Microbiology
2010; 48: 3281–3287.
Shepherd, SJ, et al.
A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. Journal of Clinical Virology
2013; 57: 29–35.
Klimashevskaya, S, et al.
Distinguishing acute from chronic and resolved hepatitis C virus (HCV) infections by measurement of anti-HCV immunoglobulin G avidity index. Journal of Clinical Microbiology
2007; 45: 3400–3403.
Noone, A, et al.
HIV infection in injecting drug users attending centres in England and Wales, 1990–1991. AIDS
1993; 7: 1501–1507.
Hope, VD, et al.
HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS
2005; 19: 1207–1214.
Connell, JA, et al.
Novel assay for the detection of immunoglobulin G antihuman immunodeficiency virus in untreated saliva and urine. Journal of Medical Virology
1993; 41: 159–164.
Judd, A, et al.
Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. Journal of Medical Virology
2003; 71: 49–55.
Mellor, J, et al.
Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group. Journal of General Virology
1995; 76: 2493–2507.
Murphy, G, Parry, JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Eurosurveillance
Maher, L, et al.
Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction
2006; 101: 1499–1508.
Maher, L, et al.
High hepatitis C incidence in new injecting drug users: a policy failure?
Australian and New Zealand Journal of Public Health
2007; 31: 30–35.
De, IJ, et al.
Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. American Journal of Epidemiology
1996; 143: 725–732.
Latkin, CA, Vlahov, D, Anthony, JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction
1993; 88: 517–526.
Iversen, J, et al.
Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998–2008. International Journal of Drug Policy
2010; 21: 471–476.
Maher, L, et al.
Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. Journal of Gastroenterology and Hepatology
2004; 19: 1114–1120.
Hope, VD, et al.
Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?
Americal Journal of Public Health
2001; 91: 38–42.
Macalino, GE, et al.
Hepatitis C infection and incarcerated populations. International Journal of Drug Policy
2003; 15: 103–114.
Pontali, E, Ferrari, F. Prevalence of hepatitis B virus and/or hepatitis C virus co-infections in prisoners infected with the Human immunodeficiency virus. International Journal of Prisoner Health
2008; 4: 77–82.
Weild, AR, et al.
Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Communicable Disease and Public Health
2000; 3: 121–126.
van Beek, I, et al.
Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. British Medical Journal
1998; 317: 433–437.
Patrick, DM, et al.
Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Canadian Medical Association Journal
2001; 165: 889–895.
Merrall, EL, et al.
Meta-analysis of drug-related deaths soon after release from prison. Addiction
2010; 105: 1545–1554.
Pinkham, S, Stoicescu, C, Myers, B. Developing effective health interventions for women who inject drugs: key areas and recommendations for program development and policy. Advanced Preventative Medicine
Kapadia, F, et al.
Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users?
2002; 13: 738–741.